Given the poor margins in the Medical Devices division (0.4% net profit in half yearly), any reductions in sales without corresponding reductions in fixed costs could mean we are losing dollars on the sale if each of these devices....
If that is the case, rather than helping with cash-flow, it could actually be hindering.
Further guidance on what is happening would be great.
- Forums
- ASX - By Stock
- AVR
- Quarterly
Quarterly, page-85
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$18.00 |
Change
0.090(0.50%) |
Mkt cap ! $344.2M |
Open | High | Low | Value | Volume |
$18.00 | $18.00 | $18.00 | $4.374K | 243 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 681 | $17.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.22 | 11 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 681 | 17.900 |
1 | 94 | 17.810 |
2 | 451 | 17.800 |
1 | 443 | 17.700 |
1 | 26 | 17.650 |
Price($) | Vol. | No. |
---|---|---|
18.220 | 11 | 1 |
18.240 | 964 | 2 |
18.300 | 150 | 1 |
18.500 | 43 | 1 |
18.690 | 550 | 1 |
Last trade - 09.59am 16/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online